Constipation News and Research

Latest Constipation News and Research

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Adolor Corporation today announced that it has completed enrollment in its Phase 2 clinical evaluation of ADL5945 in chronic, non-cancer pain patients with opioid-induced constipation (OIC).

6 Jun 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene International Sàrl today announced results from a phase II investigator initiated study of REVLIMID (lenalidomide) in combination with Avastin (bevacizumab), docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, Ill.

6 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Women with breast cancer do not benefit from flaxseed

Flaxseed provides no benefit in easing hot flashes among breast cancer patients and postmenopausal women, according to a Mayo Clinic and North Central Cancer Treatment Group study.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

Novel compound could become an effective alternative to common narcotic analgesics

Scientists from the Florida campus of The Scripps Research Institute have for the first time accomplished a laboratory synthesis of a rare natural product isolated from the bark of a plant widely employed in traditional medicine.

23 May 2011

FDA approves SUTENT for treatment of pancreatic NET

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.

21 May 2011

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Salix Pharmaceuticals, Ltd. today announced findings from two analyses of a Phase 3 open-label study of RELISTOR (methylnaltrexone bromide) presented at the 30th Annual Scientific Meeting of the American Pain Society. The meeting is being held in Austin, TX, on May 19-21, 2011.

21 May 2011

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011

USPTO grants four key patents for Alvine's proteases to detect celiac disease

Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, today announced that the United States Patent and Trademark Office has issued four key patents: 7,943,312; 7,928,056; 7,923,532; and 7,910,541, protecting various aspects of Alvine's core technology.

19 May 2011

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.

19 May 2011

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.

19 May 2011

Synergy expands GC-C agonist technology to lower cholesterol

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has successfully completed preclinical in vitro research demonstrating the inhibition of bile acid uptake by GC-C agonists and that it plans to commence animal studies shortly. Synergy believes this is the first time that GC-C agonists have been shown to potentially lower cholesterol.

18 May 2011

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.

18 May 2011

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that positive results from its Phase 3 study evaluating EXPAREL in patients following hemorrhoidectomy will be presented at the 2011 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Vancouver, British Columbia.

16 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

Irritable Bowel Syndrome linked to bacterial overgrowth, food poisoning

Cedars-Sinai researchers have reported two advances in the understanding of Irritable Bowel Syndrome, the most common gastrointestinal disorder in the United States, affecting an estimated 30 million people.

12 May 2011

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and reiterated 2011 financial guidance.

11 May 2011

New drug targets bile acid to provide relief from constipation

Constipation is definitely not a glamorous topic. In reality, it affects nearly 30 million Americans and costs more than $1 billion annually to evaluate and treat. While not often life threatening, the pain, bloating, discomfort, and straining associated with constipation lead sufferers to focus on one thing - relief.

11 May 2011

Constipation News and Research

Latest Constipation News and Research

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Women with breast cancer do not benefit from flaxseed

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

Novel compound could become an effective alternative to common narcotic analgesics

FDA approves SUTENT for treatment of pancreatic NET

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

EMA CHMP recommends conditional marketing authorization of FAMPYRA

USPTO grants four key patents for Alvine's proteases to detect celiac disease

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Synergy expands GC-C agonist technology to lower cholesterol

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

Irritable Bowel Syndrome linked to bacterial overgrowth, food poisoning

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

New drug targets bile acid to provide relief from constipation

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Constipation News and Research

Latest Constipation News and Research

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Newsletters you may be interested in